Morse Asset Management Inc Acquires 2,459 Shares of Johnson & Johnson (NYSE:JNJ)

Morse Asset Management Inc lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,689 shares of the company’s stock after purchasing an additional 2,459 shares during the period. Johnson & Johnson comprises approximately 1.8% of Morse Asset Management Inc’s investment portfolio, making the stock its 15th largest holding. Morse Asset Management Inc’s holdings in Johnson & Johnson were worth $5,760,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Winslow Evans & Crocker Inc. raised its position in shares of Johnson & Johnson by 0.3% in the 2nd quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after acquiring an additional 69 shares in the last quarter. Lathrop Investment Management Corp increased its position in Johnson & Johnson by 1.4% during the 2nd quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock valued at $689,000 after buying an additional 69 shares in the last quarter. Reik & CO. LLC increased its position in Johnson & Johnson by 0.4% during the 2nd quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock valued at $2,493,000 after buying an additional 70 shares in the last quarter. Delta Investment Management LLC increased its position in Johnson & Johnson by 1.0% during the 2nd quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock valued at $1,041,000 after buying an additional 71 shares in the last quarter. Finally, IFG Advisory LLC increased its position in Johnson & Johnson by 0.4% during the 2nd quarter. IFG Advisory LLC now owns 16,170 shares of the company’s stock valued at $2,274,000 after buying an additional 71 shares in the last quarter. Institutional investors own 67.44% of the company’s stock.

In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by corporate insiders.

Several research analysts recently issued reports on the company. Credit Suisse Group upped their target price on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Friday. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Cantor Fitzgerald upped their target price on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and an average target price of $164.93.

Johnson & Johnson stock opened at $146.36 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The business’s 50-day simple moving average is $145.51 and its two-hundred day simple moving average is $146.57. The company has a market cap of $385.30 billion, a PE ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. During the same quarter in the prior year, the business earned $2.12 earnings per share. The company’s revenue was up 1.7% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 7.99 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.76%. Johnson & Johnson’s payout ratio is 46.54%.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: How to Invest in a Bull Market

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.